| 88.37 -8.64 (-8.91%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 107.47 |
1-year : | 117.95 |
| Resists | First : | 92.01 |
Second : | 100.98 |
| Pivot price | 86.79  |
|||
| Supports | First : | 77.5 |
Second : | 64.48 |
| MAs | MA(5) : | 93.84 |
MA(20) : | 86.3 |
| MA(100) : | 94.56 |
MA(250) : | 75.28 |
|
| MACD | MACD : | 0.4 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 75.6 |
D(3) : | 86.5 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 155.28 | Low : | 22.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INBX ] has closed below upper band by 43.2%. Bollinger Bands are 20.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 96.18 - 96.78 | 96.78 - 97.2 |
| Low: | 85.68 - 86.38 | 86.38 - 86.87 |
| Close: | 87.45 - 88.48 | 88.48 - 89.2 |
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Sat, 15 Aug 2026
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors? - simplywall.st
Fri, 14 Aug 2026
Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position - Stock Titan
Fri, 14 Aug 2026
Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing - Stock Titan
Fri, 14 Aug 2026
Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss - MarketBeat
Fri, 14 Aug 2026
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Thu, 13 Aug 2026
Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 8.37e+006 (%) |
| Held by Institutions | 23.1 (%) |
| Shares Short | 3,300 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2071e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 465.4 % |
| Return on Equity (ttm) | -36.1 % |
| Qtrly Rev. Growth | 1.3e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -100.77 |
| EBITDA (p.s.) | -2.8429e+007 |
| Qtrly Earnings Growth | -8.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -132 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.88 |
| Price to Cash Flow | -216.02 |
| Dividend | 0 |
| Forward Dividend | 3.43e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|